Cancer Drugs Fund: How New Oncology Medicines Reach NHS Patients

A guide to the CDF pathway from MHRA licensing through NICE appraisal and into routine NHS supply.

When a new cancer medicine receives its UK marketing authorisation from the MHRA, the journey to a patient's treatment plan is only beginning. Between licensing and routine NHS availability sits a series of appraisal, funding, and procurement decisions that can take months or years to navigate. The Cancer Drugs Fund (CDF) exists to bridge part of that gap — but understanding how it works, and where community pharmacy fits, requires following the full decision pathway.

From MHRA licence to NICE technology appraisal

Every new oncology medicine approved by the MHRA is referred to the National Institute for Health and Care Excellence (NICE) for a technology appraisal (TA). NICE assesses clinical effectiveness and cost-effectiveness against established comparators, drawing on manufacturer submissions, clinical trial data, and independent academic review.

NICE can reach one of three outcomes:

NICE decision	What it means	Typical timeline
Recommended	NHS England must fund within 90 days of guidance publication	3–12 months post-licence
Optimised	Recommended for a narrower patient subgroup than the full licence	3–12 months post-licence
Not recommended	NHS England is not required to fund the medicine routinely	Variable

According to NICE's published data, the median time from MHRA licence to final NICE TA publication was approximately 14 months across oncology appraisals completed in 2024–2025. This figure varies considerably by therapy area and evidence maturity.

Where the Cancer Drugs Fund intervenes

When NICE's appraisal committee concludes that a cancer medicine shows clinical promise but faces uncertainty — typically around long-term survival data or cost-effectiveness — it can recommend the drug for use within the CDF rather than issuing a straight rejection.

CDF entry means:

Managed access: the medicine is available on the NHS, but only within a defined managed access agreement (MAA) specifying which patients qualify, what data must be collected, and how long the agreement lasts (typically two to three years).
Data collection: NHS trusts and treating clinicians submit real-world outcomes data through the Systemic Anti-Cancer Therapy (SACT) dataset, which feeds back into a subsequent NICE re-appraisal.
Commercial arrangement: NHS England negotiates a confidential commercial access agreement with the manufacturer, often involving a discounted price or outcomes-based rebate.

As of early 2026, NHS England reported approximately 80 cancer medicines within active CDF managed access agreements, according to published CDF list data. Not all of these are new — some have been through one or more re-appraisal cycles.

The re-appraisal cycle

Every CDF-funded medicine faces a scheduled NICE re-appraisal, typically after two to three years of managed access. At re-appraisal, NICE reviews the accumulated real-world data alongside updated manufacturer submissions and can:

Recommend for routine commissioning — the medicine exits the CDF and becomes a standard NHS treatment, funded through normal specialised commissioning budgets.
Extend managed access — if uncertainty remains, a further data-collection period may be agreed.
Remove from the CDF — if real-world evidence does not support continued funding, NHS England ceases to fund the medicine. Patients already receiving treatment typically continue under clinical discretion.

This cycle means that the CDF is not a permanent funding stream. It is, by design, a time-limited bridge between initial promise and confirmed value.

What this means for community pharmacy

Most CDF medicines are administered in hospital settings — intravenous chemotherapy, subcutaneous biologics, or specialist oral therapies initiated and monitored by oncology teams. Community pharmacy's direct role in CDF dispensing is limited, but not absent.

A growing number of oral oncology medicines are prescribed by hospital consultants and dispensed through community pharmacy or homecare providers. Where a CDF-funded oral therapy is dispensed in the community, pharmacists should be aware of several practical considerations:

Shared care protocols: the prescribing trust will issue a shared care protocol specifying monitoring requirements, supply arrangements, and communication pathways. Community pharmacists should not dispense without sight of this protocol.
SACT data obligations: the prescribing trust is responsible for SACT data submission, but any dispensing pharmacist who notices treatment breaks, dose changes, or patient-reported side effects should communicate these to the treating team.
Patient counselling: patients on CDF-funded medicines may not fully understand that their treatment is conditionally funded. Pharmacists can direct questions about treatment continuity to the prescribing oncology team.

PharmSee's analysis of 1,742 active pharmacy vacancies across 11 sources shows that 491 are listed through NHS Jobs, many of which are hospital-based roles where CDF dispensing knowledge is directly relevant. For pharmacists considering a move into hospital or oncology pharmacy roles, understanding the CDF pathway is increasingly expected at interview.

The bigger picture

The CDF pathway illustrates a broader NHS principle: that access to new medicines is governed not by licensing alone but by an evidence-and-value framework. Similar pathways exist for non-cancer medicines through NICE's standard TA process and through the Innovative Medicines Fund (IMF), which extends the managed-access model to non-oncology therapies.

For community pharmacists, the practical takeaway is that "MHRA approved" does not mean "available on the NHS". When patients ask why a medicine they have read about is not yet prescribed, the answer often lies somewhere in this appraisal pathway.

PharmSee